You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股表現》和鉑醫藥-B(02142.HK)暗盤高開17%報14.5元
阿思達克 12-09 16:16
根據輝立交易平台顯示,明天掛牌的和鉑醫藥-B(02142.HK)暗盤高開17%報14.5元獲承接,最高見16元,現造15元,較上市價12.38元,高21%,成交78萬股。

和鉑是一家仍處於臨床階段的生物製藥公司,主要從事研發免疫與腫瘤疾病領域的差異化抗體療法。是次在港上市共發售約1.38億股,並已引入Black Rock Funds、HBM Health、高瓴資本、Hudson Bay Capital、Octagon及安瀾資本等9個基石投資者,合共認購5,761.2萬股;其中10%公開發售獲77.5倍超購,已啟動回撥機制佔比增至40%,認購一手中籤率僅10%;股份以略高於招股範圍(11.7-12.92元)中間位定價,料集資淨額約15.99億元,主要用作研發核心產品HBM9161與及HBM9036、開發支柱資產HBM4003、註冊備案和潛在商業化、用於其他候選藥物研發、和鉑抗體平台產生創新型分子發現及合作項目等。上市聯席保薦人分別為大摩、美國銀行及中信証券。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account